Trials / Completed
CompletedNCT01159730
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 or Placebo |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-07-09
- Last updated
- 2011-11-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01159730. Inclusion in this directory is not an endorsement.